Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EXOSC9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EXOSC9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EXOSC9_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EXOSC9_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00710253 | Skin | cSCC | RNA surveillance | 10/4864 | 15/18723 | 1.10e-03 | 7.24e-03 | 10 |
GO:00160783 | Skin | cSCC | tRNA catabolic process | 9/4864 | 13/18723 | 1.33e-03 | 8.50e-03 | 9 |
GO:003030722 | Skin | cSCC | positive regulation of cell growth | 61/4864 | 166/18723 | 1.39e-03 | 8.78e-03 | 61 |
GO:00344272 | Skin | cSCC | nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5' | 8/4864 | 11/18723 | 1.56e-03 | 9.60e-03 | 8 |
GO:00063993 | Skin | cSCC | tRNA metabolic process | 64/4864 | 179/18723 | 2.34e-03 | 1.36e-02 | 64 |
GO:00160753 | Skin | cSCC | rRNA catabolic process | 12/4864 | 21/18723 | 2.40e-03 | 1.38e-02 | 12 |
GO:00346614 | Skin | cSCC | ncRNA catabolic process | 20/4864 | 43/18723 | 2.91e-03 | 1.62e-02 | 20 |
GO:0043628 | Skin | cSCC | ncRNA 3'-end processing | 22/4864 | 50/18723 | 4.31e-03 | 2.27e-02 | 22 |
GO:004592719 | Skin | cSCC | positive regulation of growth | 85/4864 | 259/18723 | 8.03e-03 | 3.73e-02 | 85 |
GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
GO:0006364112 | Thyroid | PTC | rRNA processing | 156/5968 | 225/18723 | 5.58e-31 | 5.03e-28 | 156 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
GO:0016072112 | Thyroid | PTC | rRNA metabolic process | 160/5968 | 236/18723 | 5.68e-30 | 3.58e-27 | 160 |
GO:1903311112 | Thyroid | PTC | regulation of mRNA metabolic process | 181/5968 | 288/18723 | 1.60e-27 | 5.94e-25 | 181 |
GO:003447018 | Thyroid | PTC | ncRNA processing | 215/5968 | 395/18723 | 7.14e-21 | 1.22e-18 | 215 |
GO:0006401112 | Thyroid | PTC | RNA catabolic process | 163/5968 | 278/18723 | 2.13e-20 | 3.27e-18 | 163 |
GO:0006402112 | Thyroid | PTC | mRNA catabolic process | 139/5968 | 232/18723 | 9.59e-19 | 1.12e-16 | 139 |
GO:0006417113 | Thyroid | PTC | regulation of translation | 236/5968 | 468/18723 | 2.70e-17 | 2.52e-15 | 236 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EXOSC9 | SNV | Missense_Mutation | | c.1321N>T | p.Pro441Ser | p.P441S | Q06265 | protein_coding | tolerated_low_confidence(0.85) | benign(0.001) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
EXOSC9 | SNV | Missense_Mutation | | c.55N>A | p.Glu19Lys | p.E19K | Q06265 | protein_coding | tolerated(0.67) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EXOSC9 | SNV | Missense_Mutation | rs761262917 | c.271G>A | p.Glu91Lys | p.E91K | Q06265 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EXOSC9 | SNV | Missense_Mutation | | c.1100N>C | p.Ile367Thr | p.I367T | Q06265 | protein_coding | tolerated_low_confidence(0.98) | benign(0.001) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
EXOSC9 | SNV | Missense_Mutation | | c.1274C>G | p.Pro425Arg | p.P425R | Q06265 | protein_coding | deleterious_low_confidence(0.02) | benign(0.232) | TCGA-E9-A1R2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
EXOSC9 | SNV | Missense_Mutation | novel | c.421N>T | p.His141Tyr | p.H141Y | Q06265 | protein_coding | deleterious(0.02) | possibly_damaging(0.637) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
EXOSC9 | SNV | Missense_Mutation | | c.332G>C | p.Arg111Thr | p.R111T | Q06265 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
EXOSC9 | SNV | Missense_Mutation | | c.1075G>A | p.Glu359Lys | p.E359K | Q06265 | protein_coding | tolerated_low_confidence(0.2) | benign(0.11) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
EXOSC9 | SNV | Missense_Mutation | rs201224124 | c.1303G>A | p.Ala435Thr | p.A435T | Q06265 | protein_coding | tolerated_low_confidence(0.48) | benign(0.036) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EXOSC9 | SNV | Missense_Mutation | | c.418A>C | p.Asn140His | p.N140H | Q06265 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |